Ovid Therapeutics Company Insiders

OVID Stock  USD 0.66  0.04  5.71%   
Ovid Therapeutics employs about 25 people. The company is managed by 18 executives with a total tenure of roughly 9 years, averaging almost 0.0 years of service per executive, having 1.39 employees per reported executive. Evaluation of Ovid Therapeutics' management performance can provide insight into the firm performance.
Dirk Haasner  President
Senior Vice President - Global Regulatory Affairs
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

Ovid Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3604) % which means that it has lost $0.3604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3661) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Ovid Therapeutics Workforce Comparison

Ovid Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 882. Ovid Therapeutics holds roughly 25.0 in number of employees claiming about 2.83% of equities under Health Care industry.

Ovid Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ovid Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ovid Therapeutics Notable Stakeholders

An Ovid Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ovid Therapeutics often face trade-offs trying to please all of them. Ovid Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ovid Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dirk HaasnerSenior Vice President - Global Regulatory AffairsProfile
Meg AlexanderChief OfficerProfile
Claude MDHead RDProfile
SPHR SHRMSCPVP FacilitiesProfile
Jason MBAChief OfficerProfile
Lora PikeSenior RelationsProfile
Garret BonneyInvestor OfficerProfile
MBA JDGeneral CounselProfile
Simon KelnerChief OfficerProfile
Zoology DphilCEO PresProfile
Julia TsaiSenior DevelopmentProfile
Tom ParryVice DevelopmentProfile
Toshiya DVMHead ResearchProfile
Zhong ZhongChief OfficerProfile
Manoj MDChief OfficerProfile
DSc FACPFounder BoardProfile
Jeffrey RonaPrincipal OfficerProfile
MPH MDSenior AffairsProfile

About Ovid Therapeutics Management Performance

The success or failure of an entity such as Ovid Therapeutics often depends on how effective the management is. Ovid Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ovid management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ovid management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was incorporated in 2014 and is headquartered in New York, New York. Ovid Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
Please note, the presentation of Ovid Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.

Ovid Therapeutics Workforce Analysis

Traditionally, organizations such as Ovid Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ovid Therapeutics within its industry.

Ovid Therapeutics Manpower Efficiency

Return on Ovid Therapeutics Manpower

Revenue Per Employee15.7K
Revenue Per Executive21.8K
Net Loss Per Employee2.1M
Net Loss Per Executive2.9M
Working Capital Per Employee3.9M
Working Capital Per Executive5.5M

Complementary Tools for Ovid Stock analysis

When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope